Citius Oncology, Inc. CTOR Pre-Tax Income
Pre-Tax Income at other companies
Other financials
Where this comes from
Reported directly by Citius Oncology, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.
The official record: Citius Oncology, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about Citius Oncology, Inc.'s pre-tax income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Citius Oncology, Inc.'s pre-tax income?
- Citius Oncology, Inc. (CTOR) reported pre-tax income of -$26.84M in Q1 2026.
- How has Citius Oncology, Inc.'s pre-tax income changed year-over-year?
- Citius Oncology, Inc.'s pre-tax income decreased by 259.3% year-over-year, from -$7.47M to -$26.84M.
- What is the long-term trend for Citius Oncology, Inc.'s pre-tax income?
- Over 2 years (2023 to 2025), Citius Oncology, Inc.'s pre-tax income has grown at a 39.8% compound annual growth rate (CAGR), from -$12.12M to -$23.7M.
- What does pre-tax income mean?
- Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.